Exclusive: Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years
Biogen execs on Thursday tried to level with their Aduhelm sales staff and prep for a 28-day blitz to convince CMS to reverse or loosen its recent decision to only cover the controversial Alzheimer’s drug in clinical trials.
Its back against the wall, the company faces an Aduhelm launch that never materialized and growing ire from investors as they try to generate some of the glittering billions in blockbuster sales analysts once so confidently forecast.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
